Originally published by our sister publication Infectious Disease Special Edition
The FDA approved a new 5-in-1 meningococcal vaccine (Penmenvy, GSK) for people from 10 through 25 years of age. The vaccine targets five major serogroups of Neisseria meningitidis (A, B, C, W and Y), or MenABCWY, that commonly cause invasive meningococcal disease (IMD).
The vaccine combines the antigenic components of GSK’s two well-established meningococcal vaccines, Bexsero (meningococcal group B vaccine)